Abstract:

AIM: To investigate the clinical efficacy and safety of monosialotetrahexose ganglioside (GM1) combined with mouse nerve growth factor (NGF) in the treatment of neonatal hypoxic ischemic encephalopathy (HIE).  METHODS: A total of 122 children with HIE admitted to our hospital from January 2017 to April 2018 were enrolled in the observation group and the control group (61 cases each) according to the random number table method. The control group was given monosialotetrahexosyl ganglioside sodium (20 mg+10% GS injection 30-50 mL, once a day), while the observation group was given mouse nerve growth factor sodium (20 mg+10% GS injection 30-50 mL, once a day) + mouse nerve growth factor (18 μg + 2 mL water for injection, intramuscular injection, once a day); two groups of children were treated for 14 days. The clinical efficacy, neurological function, mental development and motor development of two groups were compared. The conscious reflex, sucking reflex, and muscle tension recovery time of two groups were recorded. The determination of insulin-like growth factor-1 (IGF-1), serum myelin basic protein (MBP), neuron specific enolase (NSE), vascular endothelial growth factor (VEGF) and S-100β levels of two groups were detected. RESULTS:The clinical effective rate was 93.44%(57/61) in the observation group and 80.33%(49/61) in the control group. The difference was statistically significant (Z=4.604, P<0.05). The neurological measurement scale (NBNA) score of the observation group at 28 days after birth was significantly higher than that of the control group (P<0.05). The mental development index (MDI) and psychomotor development index (PDI) scores of the observation group were higher than those of the control group at 3 months after birth (P<0.05). During the treatment period, the recovery time of conscious reflex, the recovery time of sucking reflex and the recovery time of muscle tension were significantly shorter in the observation group than in the control group (P<0.05). The levels of IGF-1 were increased after treatment, and the levels of MBP, NSE, VEGF and S-100β were decreased (P<0.05). The improvement of the above indicators in the observation group was better than that of the control group (P<0.05). CONCLUSION: GM1 combined with mouse nerve growth factor has a significant effect on the treatment of HIE, which can significantly improve the neurological function of children, shorten the recovery time and reduce the serum related factors.

Key words: mouse nerve growth factor, hypoxic ischemic encephalopathy, neonatal, neurological function